Exclusive License

 

Bukwang Pharmaceutical announced that Dyna Therapeutics Co., Ltd. (Dyna) has recently obtained the exclusive rights for anti-cancer drug SOL-804. Dyna is a Project Focused Company (PFC) to specialize in developing new formulations with the goal of improving administration of drugs and reducing side effects.

Established last month, Dyna is Bukwang’s 100 percent-owned subsidiary which is designed to enhance quality of drugs, including introducing innovative formulations.

The first pipeline of Dyna is SOL-804 of Solural Pharam ApS (Solural), a treatment for castration-resistant prostate cancer. Under the licensing agreement, Dyna can develop and sell SOL-804 around the world, paving the way for exclusive development for the respective substance.

“Bukwang will consistently pursue development of new medicines, and the launch of Dyna is part of that vision,” said an official of the company, adding, “PFCs like Dyna can create high added values following independent strategies. They can enhance sociality in new drugs through flexible strategies. Specializing in innovative formulation, Dyna will be suitable for developing SOL-804.”

Dyna plans to expand its pipeline in the formulation field through vigorous research and development.

 

Copyright © BusinessKorea. Prohibited from unauthorized reproduction and redistribution